Alfred-Nobel-Str. 10
Monheim am Rhein 40789
Germany
49 2173 8955 4949
https://apontis-pharma.de
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 177
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Bruno Wohlschlegel | Chairman of Management Board | 180,96k | N/D | 1968 |
Mr. Thomas Milz | Chief Product Officer & Deputy Chairman of Management Board | 324k | N/D | N/D |
Mr. Thomas Zimmermann | Chief Financial Officer | N/D | N/D | N/D |
Mr. Harald Weyand | Head of Marketing | N/D | N/D | N/D |
Dr. Matthias Wendl | Head of Sales | N/D | N/D | N/D |
Ms. Susanne Böhm | Head of HR | N/D | N/D | N/D |
Dr. Olaf Randerath | Head of Medicine | N/D | N/D | N/D |
Dr. Susanne Endreß | Head of QA, Drug Safety & Regulatory Affairs | N/D | N/D | N/D |
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.
L'ISS Governance QualityScore di Apontis Pharma AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.